Skip to main content
SpringerLink
Log in

Primary pulmonary hypertension

  • Published:
Current Treatment Options in Cardiovascular Medicine Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References and Recommended Reading

  1. Rubin LJ: Primary pulmonary hypertension. N Engl J Med 1997, 336:111–117. This article provides a comprehensive review of primary pulmonary hypertension from a clinical perspective.

    Article  PubMed  CAS  Google Scholar 

  2. Abenhaim L, Moride Y, Brenot F, et al.: Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med 1996, 335:609–616.

    Article  PubMed  CAS  Google Scholar 

  3. Executive summary from the World Symposium on Primary Pulmonary Hypertension 1998 Web page. http://www.who.int/ncd/cvd/pph.html.

  4. Morse JH, Jones AC, Barst RJ, et al.: Mapping of familial primary pulmonary hypertension locus (PPH1) to chromosome 2q31-32. Circulation 1997, 95:2603–2606.

    PubMed  CAS  Google Scholar 

  5. Ricciardi MJ, Knight BP, Martinez FJ, et al.: Inhaled nitric oxide in primary pulmonary hypertension: a safe and effective agent for predicting response to nifedipine. J Am Coll Cardiol 1998, 32:1068–1073.

    Article  PubMed  CAS  Google Scholar 

  6. McLaughlin VV, Genthner DE, Panella MM, et al.: Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med 1998, 338:273–277. This study describes the short- and long-term effects of prostacyclin as a therapy for pulmonary hypertension and supplies unique data supporting the possibility that prostacyclin may cause reversal of vascular remodeling.

    Article  PubMed  CAS  Google Scholar 

  7. Rich S, Brundage BH: High-dose calcium channelblocking therapy for primary pulmonary hypertension: evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy. Circulation 1987, 76:135–141.

    PubMed  CAS  Google Scholar 

  8. Rich S, Kaufmann E, Levy PS: The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992, 327:76–81. This paper describes the effectiveness of calcium channel blockers and warfarin anticoagulants in prolonging survival in patients with primary pulmonary hypertension.

    Article  PubMed  CAS  Google Scholar 

  9. Packer M, Medina N, Yushak M: Adverse hemodynamic and clinical effects of calcium channel blockage in pulmonary hypertension secondary to obliterative pulmonary vascular disease. J Am Coll Cardiol 1984, 4:890–901.

    Article  PubMed  CAS  Google Scholar 

  10. Barst RJ, Rubin LJ, Long WA, et al.: A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996, 334:296–301.

    Article  PubMed  CAS  Google Scholar 

  11. Shapiro SM, Oudiz RJ, Cao T, et al.: Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion. J Am Coll Cardiol 1997, 30:343–349.

    Article  PubMed  CAS  Google Scholar 

  12. McLaughlin VV, Genthner DE, Panella MM, et al.: Compassionate use of continuous prostacyclin in the management of secondary pulmonary hypertension: a case series. Ann Intern Med 1999, 130:740–743.

    PubMed  CAS  Google Scholar 

  13. Reitz BA, Wallwork JL, Hunt SA, et al.: Heart-lung transplantation: successful therapy for patients with pulmonary vascular disease. N Engl J Med 1982, 306:557–564.

    Article  PubMed  CAS  Google Scholar 

  14. Kaiser LR, Cooper JD: The current status of lung transplantation. Adv Surg 1992, 25:259–307.

    PubMed  CAS  Google Scholar 

  15. Mikhail G, Gibbs J, Richardson M, et al.: An evaluation of nebulized prostacyclin in patients with primary and secondary pulmonary hypertension. Eur Heart J 1997, 18:1499–1504.

    PubMed  CAS  Google Scholar 

  16. Saji T, Ozawa Y, Ishikita T, et al.: Short-term hemodynamic effect of a new oral PGI2 analogue, beraprost, in primary and secondary pulmonary hypertension. Am J Cardiol 1996, 78:244–247.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Rush Medical College, Rush-Presbyterian-St. Luke’s Medical Center, 1725 West Harrison Street, Suite 020, 60612, Chicago, IL, USA

    Stuart Rich MD

Authors
  1. Stuart Rich MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rich, S. Primary pulmonary hypertension. Curr Treat Options Cardio Med 2, 135–139 (2000). https://doi.org/10.1007/s11936-000-0006-1

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11936-000-0006-1

Keywords

Search

Navigation